Utilizing Treatment Free Survival as an Endpoint in Research
BY MEREDITH M. REGAN, SCD
First-in-Human Trial for Tebentafusp In Advanced Melanoma Shows Promising Safety Profile
BY ALEXANDER N. SHOUSHTARI, MD
Expert Discusses Studying irAEs in Patients With ICC
BY SARAH ABOU ALAIWI, MD
Expert Discusses Updates in Thyroid Cancer
BY MARCIA BROSE, MD, PHD
Treatment Options For Patients With Neuroendocrine Tumors
BY MATTHEW KULKE, MD
Expanding Treatment in The Neoadjuvant Setting
BY ASHISH SAXENA, MD, PHD
Expert Discusses KRAS G12C Inhibitors for Patients with NSCLC
BY BOB T. LI, MD, MPH
Chemotherapy and Immunotherapy Combinations are The Future of NSCLC Treatment
BY CATHERINE SHU, MD
Avoiding Needless Testing in NSCLC Treatment
BY TAOFEEK OWONIKOKO, MD, PHD, MSCR
Utilizing Actionable Classifications in TNBC
BY ADITYA BARDIA, MD, MPH
External Resources
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.